PDS Biotechnology Corp PDSB
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
PDS Biotechnology Corp (PDSB) is a healthcare company listed in the US with a market value of about $107M.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -90%.
About PDS Biotechnology
PDS Biotechnology is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. It was profitable in 0 of the last 10 years in our data. Its share count rose by 62% over three years (dilution for shareholders).
Score: 0.6 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$34M | -$38M | -$43M | -$41M | -$17M | -$15M | -$7M | -$4M | -$51M | -$39M |
| Free cash flow | -$28M | -$35M | -$34M | — | — | — | — | -$2M | -$41M | -$33M |
| EPS (diluted) | $-0.74 | $-1.03 | $-1.39 | $-1.43 | $-0.66 | $-0.89 | $-1.44 | $1.15 | $-1.67 | $-1.34 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -145.4% | -125.8% | -91.3% | -60.2% | -26.6% | -53.7% | -170.5% | — | -255.0% | -36.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $4.50, 416% above the current price; targets range from $4.00 to $5.00; the consensus rating is “Strong buy”; expected EPS is $-0.44 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does PDS Biotechnology pay a dividend?
Not currently.
Is PDS Biotechnology a good stock to buy?
We do not give buy or sell advice. PDS Biotechnology scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.